Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
Eric R Chen,1 Peter K Kaiser2 1School of Medicine, Case Western Reserve University, Cleveland, OH, USA; 2Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USACorrespondence: Peter K KaiserCole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk i3-125, Cleveland, OH 44...
Guardado en:
Autores principales: | Chen ER, Kaiser PK |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/60b76b3947b14542a819c4a9a24895dd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi NA, et al.
Publicado: (2019) -
A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin P, et al.
Publicado: (2016) -
Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study
por: Asahi MG, et al.
Publicado: (2020) -
Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
por: Leys AM, et al.
Publicado: (2020) -
Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study
por: Sagong M, et al.
Publicado: (2021)